Biotech

All Articles

Amgen files first phase 3 win for $400M chronic eczema medicine

.Amgen has shared (PDF) the first phase 3 data on its $400 million dermatitis medicine, linking the ...

Biogen, UCB report period 3 lupus win after neglecting earlier test

.Biogen and also UCB's gamble on advancing right into phase 3 astride a failed research hopes to hav...

Aptadir hopes new RNA preventions can easily turn around complicated cancers cells

.Italian biotech Aptadir Therapies has released with the promise that its pipe of preclinical RNA pr...

Wave surfs DMD effectiveness to regulators' doors, sending out stockpile

.Wave Lifestyle Sciences has actually satisfied its objective in a Duchenne muscular dystrophy (DMD)...

Sanofi picks new CSO coming from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma layer...

Achilles drips tissue therapy program, prepares for discharges after overlooking 'business viability' targets

.Achilles Therapies has actually wrecked its method. The British biotech is quiting working on its c...

Aligos heralds stage 2 MASH win, lowering liver fat approximately 46%

.Aligos Rehabs is trumpeting a midstage win in metabolic-dysfunction associated steatohepatitis (MAS...

Basilea scores $268M BARDA financing for antifungals, antibiotics

.Basilea Pharmaceutica's work building brand new antifungals has gotten a considerable boost from th...

Capricor markets Europe rights to late-stage DMD treatment for $35M

.Possessing presently scooped up the U.S. rights to Capricor Therapies' late-stage Duchenne muscular...

FDA fragments adcomm for Applied's unusual illness drug

.After pushing back the selection date for Applied Rehabs' metabolic problem medication govorestat, ...